Beijing, February 24, 2025 – A newly identified bat coronavirus, designated HKU5-CoV-2, has been found to enter human cells using the same cell-surface protein as SARS-CoV-2, the virus responsible for COVID-19, according to a study published in the journal Cell.

While the virus possesses key features such as a furin cleavage site that facilitates entry via the ACE2 receptor, researchers noted that it does not infect human cells as efficiently as SARS-CoV-2.

In laboratory experiments, HKU5-CoV-2 successfully infected human cells with high ACE2 levels in both test tube assays and in models simulating human intestinal and airway tissues. The study further identified several monoclonal antibodies and antiviral drugs capable of targeting the bat virus, offering potential avenues for preemptive therapeutic strategies.

The research has attracted significant market attention; Bloomberg reported that news of the study influenced a modest rise in shares of several COVID vaccine manufacturers, including Pfizer, Moderna, and Novavax. However, infectious disease expert Dr. Michael Osterholm from the University of Minnesota cautioned that the reaction might be “overblown.” He pointed to the extensive preexisting immunity in the global population against similar SARS viruses and the markedly lower binding affinity of HKU5-CoV-2 to human ACE2 compared with SARS-CoV-2, factors that could mitigate the pandemic risk.

While the discovery highlights a potential pathway for zoonotic spillover, the authors of the study stressed that several suboptimal factors for human adaptation suggest that the risk of this bat virus emerging as a human pathogen should not be exaggerated. The findings add to the growing body of research on coronaviruses and underscore the importance of continued surveillance of wildlife pathogens.

Copied